Edgewise Therapeutics (EWTX) Equity Average (2020 - 2026)

Edgewise Therapeutics has disclosed Equity Average across 7 years of filings, most recently posting $507.7 million for Q1 2026.

• Equity Average for Q1 2026 came in at $507.7 million, up 14.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.7 million (up 14.23% YoY), and the FY2025 annual result was $490.7 million, up 26.15% from the prior year.
• Equity Average came in at $507.7 million for Q1 2026 at Edgewise Therapeutics, down from $540.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $573.9 million in Q3 2025 to a low of $253.4 million in Q2 2022.
• The 5-year median for Equity Average is $426.9 million (2024), against an average of $408.3 million.
• Peak annual rise in Equity Average reached 95.89% in 2022, while the deepest fall reached 15.99% in 2022.
• Edgewise Therapeutics' Equity Average stood at $354.1 million in 2022, then retreated by 13.96% to $304.6 million in 2023, then soared by 55.61% to $474.0 million in 2024, then advanced by 14.01% to $540.5 million in 2025, then declined by 6.05% to $507.7 million in 2026.
• The last three Equity Average figures came in at $507.7 million (Q1 2026), $540.5 million (Q4 2025), and $573.9 million (Q3 2025), per Business Quant data.